With da­ta to pro­pel it in­to PhI­II, 89bio asks mar­ket for near­ly $100M to bankroll ex-Te­va drug

89bio, born out of a Te­va drug, is the lat­est to board the speed rail that takes biotechs from pos­i­tive clin­i­cal da­ta drop to cash re­quest with­in a minute.

The San Fran­cis­co biotech re­vealed a mid-stage test that passed muster in a high-fat con­di­tion that some­times leads to car­dio­vas­cu­lar dis­ease, and a minute af­ter­wards in a Tues­day post-mar­ket re­lease, 89bio asked in­vestors for $75 mil­lion. Hours lat­er, past mid­night, they up­sized the pub­lic of­fer­ing to $94.5 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER